3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
6
Breast
3
Gastrointestinal
1
Conditions
Colorectal Neoplasms
24
Breast Neoplasms
14
Colonic Neoplasms
11
Rectal Neoplasms
9
Pancreatic Neoplasms
9
Lung Neoplasms
8
Uterine Cervical Neoplasms
5
Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Prostatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
3
Lymphoma
3
Anxiety Disorders
3
Pancreatic Cyst
2
Melanoma
2
Leukemia
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease
2
Depression
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Weight Loss
1
Vulvar Neoplasms
1
Uterine Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Interventions
fludarabine
3
Vaccines
3
Radiotherapy
3
Papillomavirus Vaccines
3
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
entinostat
2
aldesleukin
2
aflibercept
2
Trastuzumab
2
Surveys and Questionnaires
2
Specimen Handling
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
durvalumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Methods
×
Gastrointestinal
×
Clear all
NCT05939440
2025-06-05
P-COC
University of Alabama at Birmingham
Phase NA
Completed
60 enrolled